Contributions
Abstract: EP1412
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Pathology
Introduction: A thorough literature research is usually the first step when dealing with a novel topic. Regarding the medical domain, a popular starting point for this task is the webpage PubMed, which has over 24Million publication in its database. Given certain keywords of interest, i.e. neurodegeneration, results are presented by PubMed in form of textual lists which can span over several hundred pages. Thus, getting a reasonable overview over published literature for a certain topic can be a very time consuming and challenging task.
Objective: Development of an innovative software allowing for a swift visualized literature research in the Multiple sclerosis medical domain.
Methods and Results: The novel web platform VILIP (Visualized-literature platform) provides an easy to operate interface for visual-based literature research in the medical domain. In this part of the project we focused on neurodegenerative changes in Multiple sclerosis patients and its animal models. In a first step, PubMed articles of interest were imported into a personalized database. During this import process, each publication was annotated with keywords and subsequently assigned to an anatomic, cellular or biochemical structure/item. Once all papers have been imported, the visualization process can be started. Given one or several search terms the domain-frequency of the papers are automatically visualized by an in-situ heat-map. This allows for a rapid overview of the amount of publications regarding neurodegeneration in the context of Multiple Sclerosis.
Conclusion: The VILIP platform provides a powerful and easy-to-use tool for rapid and time-effective literature research.
Disclosure: Caroline Roggenkamp: nothing to disclose
Malte Modlich: Daniel Klischies: nothing to disclose
Daniel Klischies: nothing to disclose
Christian Kohlschein: nothing to disclose
Markus Kipp: nothing to disclose
This study was supported by Novartis Pharma GmbH - Germany.
Abstract: EP1412
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Pathology
Introduction: A thorough literature research is usually the first step when dealing with a novel topic. Regarding the medical domain, a popular starting point for this task is the webpage PubMed, which has over 24Million publication in its database. Given certain keywords of interest, i.e. neurodegeneration, results are presented by PubMed in form of textual lists which can span over several hundred pages. Thus, getting a reasonable overview over published literature for a certain topic can be a very time consuming and challenging task.
Objective: Development of an innovative software allowing for a swift visualized literature research in the Multiple sclerosis medical domain.
Methods and Results: The novel web platform VILIP (Visualized-literature platform) provides an easy to operate interface for visual-based literature research in the medical domain. In this part of the project we focused on neurodegenerative changes in Multiple sclerosis patients and its animal models. In a first step, PubMed articles of interest were imported into a personalized database. During this import process, each publication was annotated with keywords and subsequently assigned to an anatomic, cellular or biochemical structure/item. Once all papers have been imported, the visualization process can be started. Given one or several search terms the domain-frequency of the papers are automatically visualized by an in-situ heat-map. This allows for a rapid overview of the amount of publications regarding neurodegeneration in the context of Multiple Sclerosis.
Conclusion: The VILIP platform provides a powerful and easy-to-use tool for rapid and time-effective literature research.
Disclosure: Caroline Roggenkamp: nothing to disclose
Malte Modlich: Daniel Klischies: nothing to disclose
Daniel Klischies: nothing to disclose
Christian Kohlschein: nothing to disclose
Markus Kipp: nothing to disclose
This study was supported by Novartis Pharma GmbH - Germany.